Loading...
•
Sep 30, 2021
SpringWorks Therapeutics Q3 2021 Earnings Report
Reported financial results for the third quarter and year-to-date periods ended September 30, 2021 and provided an update on recent company developments.
Key Takeaways
SpringWorks Therapeutics reported a net loss of $41.0 million, or $0.84 per share, for the third quarter of 2021. As of September 30, 2021, cash, cash equivalents and marketable securities were $480.6 million.
Advanced into Randomized Phase 2 Expansion and Addition of New Sub-studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma.
Expanded Targeted Oncology Pipeline with In-License of Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors.
Initiated Mirdametinib Phase 1/2 Basket Study in ER+ Metastatic Breast Cancer and MEK 1/2 Mutant Solid Tumors.
Announced Issuance of New U.S. Composition of Matter Patents to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...